Long-acting, low-addictive HNK derivatives and their manufacturing method

Compounds with specific structures address the short efficacy and addiction issues of HNK derivatives by providing prolonged therapeutic benefits for depression and CRPS with reduced addictive properties.

JP7579595B2Active Publication Date: 2024-11-08HANGZHOU RUIXI BIOSCIENCE TECHNOLOGY LTD CO
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2022575338
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-08-31
Publication Date
2024-11-08
Estimated Expiration
2040-08-31

AI Technical Summary

Technical Problem

Existing HNK derivatives for treating depression and conditions like CRPS have short efficacy periods and pose a risk of addiction, limiting their therapeutic potential.

Method used

Development of compounds with structures represented by specific formulas, such as Formula I, which provide longer efficacy lasting more than one week and significantly reduce addictive properties, including salts, stereoisomers, and tautomers.

Benefits of technology

The compounds achieve prolonged therapeutic effects for depression and conditions like CRPS, with reduced addiction risk, maintaining efficacy for over a week and minimizing side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579595000036
    Figure 0007579595000036
  • Figure 0007579595000037
    Figure 0007579595000037
  • Figure 0007579595000038
    Figure 0007579595000038
Patent Text Reader

Abstract

The present application relates to compounds for antidepressant use, amelioration of anxiety and post-traumatic stress syndrome, anesthesia, analgesia, improvement of cognitive function, lung protection, prevention or treatment of amyotrophic lateral sclerosis, or prevention or treatment of complex regional pain syndrome. The compounds of the present application have a longer duration of efficacy than conventionally known HNK compounds, and further, the compounds of the present application are substantially non-addictive.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present application relates to the pharmaceutical field, specifically to a long-acting, low-addictive HNK derivative for treating depression, including complex regional pain syndrome (CRPS), and a method for preparing the same. [Background technology]

[0002] Ketamine is a representative of phencyclidine-based intravenous anesthetics commonly used in clinical practice, and is one of the anesthetics for which clinical and basic research has progressed rapidly in recent years. In clinical practice, it is often used to meet the anesthesia needs of pediatrics, obstetrics and gynecology, ceremonies, and patients with specific diseases, due to its characteristics of rapid induction, short duration of action, fast resuscitation, and mild effects on the respiratory and circulatory systems.

[0003] Ketamine was first synthesized in 1962, used in humans in 1965, and officially approved for clinical use by the FDA in 1970. Its typical "dissociative anesthesia" and short-term reliable analgesia made it popular for a time, but then its psychological side effects and the rapid development of other intravenous anesthetics were found to have significantly reduced its clinical use. Over the past decade, following research into ketamine's dosage and administration and the discovery of its anti-inflammatory, antidepressant, neuroprotective, analgesic and other effects, interest in ketamine has been rekindled in the medical community.

[0004] Ketamine's effects on pre-hospital anesthesia and analgesia cannot be ignored due to its strong analgesic effects, amnesia, simultaneous maintenance of autonomic breathing and airway defense reflexes, and maintenance of hemodynamic stability. Ketamine has both neurotoxic and neuroprotective effects.

[0005] Ketamine affects postoperative cognitive function. One researcher tested 50 children who received ketamine anesthesia and found that ketamine general anesthesia reduced cognitive function in children 6 hours after surgery, but did not affect cognitive function 24 hours after surgery. Hudetz et al. found that administering 0.5 mg / kg of ketamine during induction of general anesthesia reduced the incidence of postoperative cognitive dysfunction one week after cardiac surgery. In recent years, many clinical trials have also demonstrated that a single small dose of ketamine administered during surgery can reduce the incidence of postoperative cognitive dysfunction.

[0006] Ketamine has analgesic properties. Subanesthetic doses of ketamine are often used to treat antihyperalgesia and acute chronic pain. Studies have demonstrated that gargling with a mixture of ketamine and saline before induction of anesthesia significantly reduces the incidence and severity of postoperative sore throat caused by tracheal intubation under general anesthesia. The use of opioids during surgery increases the postoperative dose of opioids for analgesia, an effect called opioid tolerance. It has been clinically found that the use of ketamine can prevent opioid tolerance, reverse morphine tolerance, and enhance the analgesic effect of morphine. Studies have also demonstrated that the use of small amounts of ketamine during surgery can prevent remifentanil-induced postoperative hyperalgesia. Cagla et al. administered ketamine intravenously at 0.15 mg / kg postoperatively to patients undergoing knee arthroscopic surgery and found that ketamine significantly improved postoperative analgesia satisfaction and had lower sedation scores than the ketamine-midazolam combination group.

[0007] Ketamine has a lung protective effect. In recent years, ketamine has been found to have a significant lung protective effect. As demonstrated by clinical experiments, both intravenous administration and nebulized inhalation before ventilation of one lung in thoracic surgery can reduce the level of blood inflammatory factors, but nebulized inhalation is more beneficial to the cardiovascular system and airway pressure, and the nebulized effect on the ventilated side of the lung is superior to the nebulized effect on double lung. Ketamine is often used clinically in first aid for fatal asthma attacks in which normal treatment is ineffective, and it is also well recognized that its use can improve prognosis.

[0008] Ketamine has antidepressant properties. Berman et al. first reported in 2000 that more than 50% of patients had a 50% or greater decrease in the Hamilton Depression Rating Scale within 72 hours after a single intravenous injection of a subanesthetic dose of ketamine (0.5 mg / kg). In recent years, more animal and clinical studies have further demonstrated the antidepressant effects of ketamine. Ketamine is also used for anesthesia for electroconvulsive therapy in patients with depression.

[0009] The patent application, with application number CN201280062294X and title of the invention Use of (2R,6R)-Hydroxynorketamine, (S)-Dehydronorketamine, and Other Dehydro Stereoisomers and Hydroxylated Metabolites of (R,S)-Ketamine for Treating Depression and Neuropathic Pain, discloses that CNS (central nervous system) side effects are related to the activity of (R,S)-ketamine on NMDA receptors, and the application researches and synthesizes (2R,6R;2S,6S)-Hydroxynorketamine (HNK) based on ketamine, and finds that the compound has no activity on NMDA receptors, thereby avoiding possible side effects, and at the same time, the compound is said to have the effect of treating bipolar depression, severe depression, Alzheimer's dementia, amyotrophic lateral sclerosis, complex regional pain syndrome (CRPS), chronic pain, or neuropathic pain.

[0010] In this experimental study, it was found that the duration of efficacy of (2R,6R;2S,6S)-hydroxynorketamine (HNK) after administration was short, and it was essentially inactive within one week, which significantly limited the desired long-acting effect when treating depression. At the same time, this study also found that the use of HNK caused a certain degree of addiction, which had a negative effect on the patient's mind and body. Therefore, how to modify the structure of (2R,6R;2S,6S)-hydroxynorketamine (HNK) to obtain a medicine with longer efficacy and less addiction has great therapeutic potential. [Prior art documents] [Patent documents]

[0011] [Patent Document 1] CN201280062294X Summary of the Invention [Means for solving the problem]

[0012] The present application relates to compounds having the effects of antidepressant, anesthetic, analgesia, improving cognitive function, protecting the lungs, preventing or treating amyotrophic lateral sclerosis, or preventing or treating complex regional pain syndrome.

[0013] The compounds of the present application have a longer duration of efficacy than the conventionally known HNK compounds, specifically, while HNK is metabolized, i.e., inactive, within one week, the compounds of the present application can maintain their efficacy for more than one week, specifically, for more than 7 days, more than 10 days, more than 14 days, etc. Furthermore, the compounds of the present application are almost non-addictive, and their addictive potential is 2, 5, 10, or 20 times lower than that of HNK compounds.

[0014] The present application provides a compound having the structure represented by Formula I, a salt, stereoisomer, or tautomer thereof. [ka] Where: m is an integer from 0 to 3 and n is an integer from 0 to 4; R1 and R2 each independently represent H, a halogen, a hydroxy group, an amino group, a cyano group, a substituted or unsubstituted C1-C6 alkyl group, a substituted or unsubstituted C2-C6 alkenyl group, a substituted or unsubstituted C2-C6 alkynyl group, a substituted or unsubstituted C3-C 10 Cycloalkyl groups, substituted or unsubstituted C2-C 10one or more selected from a heterocyclic group, a substituted or unsubstituted C1-C6 alkoxy group, a substituted or unsubstituted mono- and di-C1-C6 alkylamino group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heteroaryl group; R3 is a halogen; R4 is selected from H, a substituted or unsubstituted C1-C6 alkyl group, a substituted or unsubstituted C1-C8 acyl group, a substituted or unsubstituted aryl acyl group, or a substituted or unsubstituted heteroaryl acyl group; R5 is a substituted or unsubstituted C3-C 10 Cycloalkyl groups, substituted or unsubstituted C2-C 10 selected from a heterocyclic group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heteroaryl group; R6 is H, a substituted or unsubstituted C1-C6 alkyl group, a substituted or unsubstituted C2-C6 alkenyl group, a substituted or unsubstituted C2-C6 alkynyl group, a substituted or unsubstituted C3-C 10 Cycloalkyl groups, substituted or unsubstituted C2-C 10 selected from a heterocyclic group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted C1-C8 acyl group, a substituted or unsubstituted arylacyl group, or a substituted or unsubstituted heteroarylacyl group; The substitutions are OH; NH2; C1-C 10 Alkyl, alkenyl or alkynyl groups; C1-C 10 Alkylamine group;Mercapto group;C1-C 10 Alkylmercapto group; C1-C 20 Alkoxy group; C1-C 10 Carbonyl group; C3-C 10 Cycloalkyl groups; 3-10 membered heterocyclic groups having one or more heteroatoms selected from N, S, O, P; C6-C 20 Aryl group; C2-C 20 Heteroaryl groups; nitrocyano groups, or halogen substituted.

[0015] Preferably, the compound is characterized in that it has a structure represented by formula II. [ka]

[0016] Preferably, the compound is characterized in that it has a structure represented by formula III. [ka] Here, p is an integer from 0 to 3.

[0017] Preferably, the compound is characterized in that it has a structure represented by formula IV. [ka] Here, p is an integer from 0 to 3.

[0018] Preferably, the compound is as described above, characterized in that it is a compound as shown below. [ka]

[0019] Preferably, the compound is as described above, characterized in that it is a compound as shown below. [ka]

[0020] The present application also provides a compound, a salt, a stereoisomer, or a tautomer thereof, having the structural formula: [ka] where R7 is H or a protecting group.

[0021] Preferably, the compound, its salt, stereoisomer, or tautomer is characterized by the structure as follows: [ka]

[0022] Preferably, the compound, its salt, stereoisomer, or tautomer is characterized by the structure as follows: [ka] or [ka]

[0023] The present application further provides a pharmaceutical composition comprising a compound according to any one of claims 1-8, a salt, a stereoisomer, or a tautomer thereof, and optionally further comprising a pharma- ceutically acceptable carrier.

[0024] The present application further provides a method for preparing a compound, characterized in that: [ka]

[0025] Application of any of the above compounds in the manufacture of a medicine for anesthesia, analgesia, improvement of cognitive function, lung protection, antidepressant, anxiety and post traumatic stress syndrome, amyotrophic lateral sclerosis, complex regional pain syndrome.

[0026] Here, the pain includes chronic pain or neuropathic pain, the depression includes bipolar depression and severe depression, anxiety and post-traumatic stress syndrome are improved, and the improvement of cognitive function includes prevention or treatment of Alzheimer's disease, Parkinson's disease, etc.

[0027] All of the above diseases include preventive or therapeutic actions.

[0028] Stereoisomers of all the above compounds include enantiomers and diastereomers.

[0029] All of the above compounds include all tautomeric forms, if the compounds exist in different tautomeric forms and the application is not limited to any one of the specific tautomeric forms.

[0030] All of the above compounds include compounds with all possible isotopes of the atoms present in the compounds. Isotopes include atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium, and isotopes of carbon include 11 C. 13 C and 14 Contains C.

[0031] The present application further provides pharmaceutical compositions, in which the compounds disclosed herein can be administered as pure chemicals, but preferably as pharmaceutical compositions. Accordingly, the present disclosure provides pharmaceutical compositions comprising the compound or a pharmaceutical salt thereof together with at least one pharmaceutical carrier. The pharmaceutical composition may comprise the compound or a salt thereof as the only active agent, but preferably comprises at least one other active agent. In certain embodiments, the pharmaceutical composition is an oral dosage form comprising about 0.1 mg to about 1000 mg, about 1 mg to about 500 mg, or about 10 mg to about 200 mg of the compound of formula I, and optionally about 0.1 mg to about 2000 mg, about 10 mg to about 1000 mg, about 100 mg to about 800 mg, or about 200 mg to about 600 mg of other active agents in a unit dosage form.

[0032] The compounds disclosed herein can be administered orally, topically, parenterally, by inhalation or spray, sublingually, transdermally, bucally, rectally, as eye drops, or by other means in dosage unit formulations containing conventional pharmaceutical carriers. Pharmaceutical compositions may be prepared into any pharmaceutical form, such as aerosols, creams, gels, pills, capsules, tablets, syrups, transdermal patches, or eye drops. Some dosage forms, such as tablets and capsules, can be subdivided into suitable dosage unit dosage forms containing an appropriate amount of active ingredient, such as an amount effective to achieve the desired purpose.

[0033] Carriers include excipients and diluents and must be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the patient being treated. Carriers may be inert or may themselves be pharma- ceutically useful.

[0034] The types of carriers include, but are not limited to, binders, buffers, colorants, diluents, disintegrants, emulsifiers, flavorings, glidants, lubricants, preservatives, stabilizers, surfactants, tableting agents, wetting agents, etc. Some carriers may be divided into several categories, for example, vegetable oils may be used as lubricants in some formulations and as diluents in other formulations. Examples of pharmaceutical carriers include sugars, starches, celluloses, powdered tragacanth, malt, gelatin, talc, and vegetable oils. Optional active agents may be included in the pharmaceutical composition without substantially affecting the activity of the compounds of the present invention.

[0035] The compound of the present application or its salt may be the only active agent administered or may be administered together with other active agents. For example, the compound of the present application may be administered together with any one of the following additional active agents: Antidepressants: escitalopram oxalate, fluoxetine, paroxetine, duloxetine, sertraline, citalopram, bupropion, venlafaxine, duloxetine, naltrexone, mirtazapine, venlafaxine, atomoxetine, bupropion, doxepin, amitriptyline, clomipramine, nortriptyline, buspirone, aripiprazole, clozapine, loxapine, olanzapine, quetiapine, risperidone, ziprasidone, carbamazepine, gabapentin, lamotrigine, phenytoin, pregabalin, donepezil, galantamine, memantine, rivastigmine, tramiprosate, or pharma- ceutically active salts or prodrugs thereof, or combinations of the above; Schizophrenia drugs: aripiprazole, lurasidone, asenapine, clozapine, ziprasidone, risperidone, quetiapine, trifluoperazine, olanzapine, clozapine, flupentixol, perphenazine, haloperidol, chlorpromazine, fluphenazine, prolixin, paliperidone; Alzheimer's Dementia Medications: Donepezil, Rivastigmine, Galantamine, Memantine; ALS medications: Riluzole; Pain Medications: Acetaminophen, Aspirin, NSAIDS (including Diclofenac, Diflunisal, Etodolac, Fenoprofen, Flurbiprofen, Ibuprofen, Indomethacin, Ketoprofen, Ketorolac, Meclofenamic Acid, Mefenamic Acid, Meloxicam, Nabumetone, Naproxen, Oxaprozin, Phenylbutazone, Piroxicam, Sulindac, Tolmetinopiods, Cox-2 Inhibitors such as Celecoxib), and Narcotic Pain Medications (e.g. Buprenorphine, Butorphanol, Codeine, Dihydrocodeinone, Hydromorphone, Levorphanol, Pethidine, Methadone, Morphine, Nalbuphine, Oxycodone, Pentazocine, Propoxyphene, Tramadol which is a central pain reliever).

[0036] The above list of other active agents is illustrative and not exhaustive. Other active agents not included in the above list can be administered in combination with the compound of formula I. In some embodiments, the other active agent is generally administered at a minimum below the prescribed dose, and in some cases below the approved dose, but may be administered according to the approved regulatory information.

[0037] The present application includes methods of treating depression, particularly methods of treating bipolar depression and major depression, particularly methods of treating treatment-resistant depression, wherein an effective amount of the compound is a dose effective to reduce symptoms of depression, wherein reduction in symptoms of depression is a 50% or greater reduction in symptoms as determined by a High Reactive Depression Scale or High Risk Depression Score (HRSD).17 score of 7 or less on the QID-SR 16 The goal is to achieve a score of 5 or less on the WHO Global Health Index (GHI) or 10 or less on the MADRS.

[0038] The present application provides an amount effective to reduce pain symptoms (or provide analgesia), where reducing pain symptoms is achieving a 50% or greater reduction in pain symptoms on a pain scale.

[0039] Terminology "Stereoisomers" are compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.

[0040] "Diastereomers" are stereoisomers that have two or more chiral centers and whose molecules are not mirror images of one another. Diastereomers have different physical properties, such as melting points, boiling points, spectral properties, and reactivity. Mixtures of diastereomers can be separated by high resolution analytical procedures, such as electrophoresis, crystallization, or the like, using a chiral HPLC column, in the presence of a resolving agent or chromatography.

[0041] "Enantiomers" refers to two stereoisomers of a compound that have no superimposable mirror images of each other. A 50:50 mixture of enantiomers is called a racemic mixture or racemate, which can occur when stereoselection or stereoorientation has been lost during a chemical reaction or process. "Alkyl group" includes both branched and straight-chain saturated aliphatic hydrocarbon groups having a specified number of carbon atoms, generally from 1 to about 12 carbon atoms. As used herein, a C1-C6 alkyl group refers to an alkyl group having 1 to 6 carbon atoms. As used herein, C0-C nWhen an alkyl group is used in combination with another group, for example, a (phenyl)C0-C4 alkyl group, in which the group is directly bonded to the phenyl with a single covalent bond (C0) or is linked via an alkyl chain having a specific number of carbon atoms (in this case, 1 to about 4 carbon atoms). Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, 3-methylbutyl, t-butyl, n-pentyl, and sec-pentyl groups.

[0042] "Alkenyl group" refers to straight and branched chains containing one or more unsaturated carbon-carbon bonds, which may occur at any one stable point along the chain. Alkenyl groups described herein generally have from 2 to about 12 carbon atoms. Alkenyl groups are preferably lower alkenyl groups having from 2 to about 8 carbon atoms, such as C2-C8, C2-C6, and C2-C4 alkenyl groups. Examples of alkenyl groups include, but are not limited to, vinyl, propenyl, butenyl, and the like.

[0043] "Alkoxy" refers to an alkyl group as defined above with the specified number of carbon atoms connected through an oxygen bridge. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, 3-hexyloxy, and 3-methylpentyloxy.

[0044] The halogens are well known in the art and are preferably F, Cl, Br, I.

[0045] The term "heterocyclo" refers to a 5-8 membered saturated, partially unsaturated, or aromatic ring containing from 1 to about 4 heteroatoms selected from N, O, and S, with the remaining ring atoms being carbon, or a 7-11 membered saturated, partially unsaturated, or aromatic heterocyclic ring system and a 10-15 membered tricyclic ring system, with at least one heteroatom selected from N, O, and S in a polycyclic ring system, and at most about 4 heteroatoms selected independently from N, O, and S in each ring of the polycyclic ring system. Unless otherwise specified, a heterocyclo may be linked to a group that may be substituted at any of its heteroatoms and carbon atoms to produce a stable structure. When specified, a heterocyclo described herein may be substituted on a carbon or nitrogen atom if the resulting compound is stable. The nitrogen atom in the heterocyclo may be optionally quaternized. The total number of heteroatoms in the heterocyclo group is preferably 4 or less, and the total number of S and O atoms in the heterocyclo group is preferably 2 or less, and more preferably 1 or less. Examples of heterocyclic groups include pyridyl, indolyl, pyrimidinyl, pyridazinyl, pyrazinyl, imidazolyl, oxazolyl, furyl, phenylthio, thiazolyl, triazolyl, tetrazolyl, isoxazolyl, quinolyl, pyrrolyl, pyrazolyl, benzo[b]thiophenyl, isoquinolyl, quinazolinyl, quinoxalinyl, thienyl, isoindolyl, dihydroisoindolyl, 5,6,7,8-tetrahydroisoquinoline, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl, and pyrrolidinyl.

[0046] "Aryl or heteroaryl group" refers to a stable 5- or 6-membered monocyclic or polycyclic ring containing 1-4, preferably 1-3, heteroatoms selected from N, O and S, with the remaining ring atoms being carbon. If the total number of S and O atoms in the heteroaryl group exceeds 1, these heteroatoms are not adjacent to each other. The total number of S and O atoms in the heteroaryl group is preferably 2 or less. It is particularly preferred that the total number of S and O atoms in the heteroaryl group is 1 or less. The nitrogen atom in the heterocyclo may be optionally quaternized. When specified, these heteroaryl groups may be substituted with carbon or non-carbon atoms or groups. Such substitution may include condensation with a 5- to 7-membered saturated ring group optionally containing 1 or 2 heteroatoms independently selected from N, O and S to form, for example, a [1,3]dioxazolo[4,5-c]pyridinyl group. Examples of heteroaryl groups include, but are not limited to, pyridyl, indolyl, pyrimidinyl, pyridazinyl, pyrazinyl, imidazolyl, oxazolyl, furyl, phenylthio, thiazolyl, triazolyl, tetrazolyl, isoxazolyl, quinolyl, pyrrolyl, pyrazolyl, benzo[b]thiophenyl, isoquinolinyl, quinazolinyl, quinoxalinyl, thienyl, isoindolyl, and 5,6,7,8-tetrahydroisoquinoline. Preferred aryl groups are phenyl, naphthyl, and the like.

[0047] "Depression" includes low mood, decreased interest in activities, sluggishness or irritability, appetite changes, lack of concentration or indecisiveness, excessive feelings of guilt or inferiority, and may also include suicidal thoughts in cases of depression, bipolar depression, and other disease or medical condition-related affective disorders, object-related affective disorders, and other affective disorders of unknown etiology, and may be present with a variety of other mental disorders (including, but not limited to, psychotic disorders, cognitive disorders, eating disorders, anxiety disorders, and personality disorders). The longitudinal course of the disease, medical history, symptom typology, and etiology help distinguish the various forms of affective disorders from each other.

[0048] "Salts of compounds" refers to derivatives of the disclosed compounds, modified by preparing the parent compound into a non-toxic acid or base addition salt, and also refers to pharmaceutical solvates of these compounds and their salts. Examples of pharmaceutical salts include, but are not limited to, inorganic or organic acid addition salts of basic residues such as amines, base or organic addition salts of acidic residues such as carboxylic acids, and combinations of one or more of the above salts. Pharmaceutical salts include non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids, and quaternary ammonium salts. For example, non-toxic acid salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, nitric acid, and other acceptable inorganic salts include metal salts such as sodium salts, potassium salts, cesium salts, alkaline earth metal salts such as calcium salts, magnesium salts, and combinations of one or more of the above salts.

[0049] Organic salts of compounds include acetic acid, trifluoroacetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, pamoic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-aminobenzenesulfanilic acid, 2-acetylbenzoic acid, fumaric acid, p-toluenesulfonic acid, methanesulfonic acid, ethanedisulfonic acid, and ethanesulfonic acid. salts prepared from organic acids such as oxalic acid, isethionic acid, HOOC-(CH2)n-COOH (where n is 0-4); organic amine salts such as triethylamine salts, pyridine salts, picoline salts, ethanolamine salts, triethanolamine salts, dicyclohexylamine salts, N,N'-dibenzylethylenediamine salts, and amino acid salts such as arginine salts, aspartate salts, glutamate salts, and combinations of one or more of these salts. [Brief description of the drawings]

[0050] [Figure 1] Antidepressant effects of different doses of the drug within 7 days. [Diagram 2]Antidepressant effects of compounds C and D. [Diagram 3] Compound I6 has no sensitizing effect. [Figure 4] Compound C has behavioral sensitizing properties. [Diagram 5] Compound D has behavioral sensitizing properties. [Figure 6] I6 has no place preference effect in mice. [Figure 7] Compound C induces place preference. [Figure 8] Compound D induces place preference. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0051] Example 1: Synthesis of (2R,6R)-6-hydroxydemethylketamine (HNK) [ka] Step 1: Add 50g of magnesium powder to a two-necked or three-necked flask, and after starting, slowly add a mixed solution of 119.2g of bromocyclopentane and THF, and reflux for 2-4 hours after the dropwise addition to obtain 1.6mol / L cyclopentyl Grignard reagent. Add 840mg of CuBr to a mixed solution of THF and o-chlorobenzonitrile (50.0g), and add cyclopentyl Grignard reagent (1.6mol / L, 280ml) dropwise under ice bath conditions. After the dropwise addition, reflux for 1 hour, cool to room temperature, add 100ml of water, add 200ml of 15% diluted sulfuric acid solution, stir overnight, spin-dry the THF, extract with EA, dry, and pass through a silica gel column to obtain 60g of 2-chlorophenyl cyclopentyl ketone, which is compound A, with a yield of 80%.

[0052] Step 2: 20g (96mmol) compound A was dissolved in 400ml EA according to the reported method (Bioorganic & Medicinal Chemistry 2013, 12,5098). After dissolution, copper bromide (54g, 242mmol) was added, and the mixture was heated under reflux for 3 hours, then cooled to room temperature. The solid insoluble matter was filtered through Celite, and dichloromethane was added to wash the residue. The mixture was then combined with the filtrate and concentrated to obtain 2-chlorophenyl(1-bromocyclopentyl)methanone, a yellow oily compound B. The mixture was passed through a silica gel column to obtain 22g of pure compound B, with a yield of 80%.

[0053] Step 3: Ammonia gas was introduced into 200ml of ammonia water until saturation, and compound B (10g) was added and stirred for 24 hours to precipitate compound C. The precipitate was filtered and dried to obtain compound C (7g) as a brown solid, which was directly used in the next step with a yield of 70%.

[0054] Step 4: Compound C (5 g) was dissolved in dry THF, and HCl gas was introduced until the pH of the solution reached 1. The solution was spin-dried to obtain a solid hydrochloride. The solid hydrochloride was placed in a one-neck flask and placed in an oil bath at 190° C. under nitrogen protection for about 20 minutes, cooled to room temperature, neutralized with saturated sodium bicarbonate solution, extracted with DCM, and then concentrated and crystallized to obtain compound D, demethylated ketamine HNK racemate, 2.9 g, with a yield of 75%. 1 HNMR(400MHz,CDCl3):δ7.67(dd,J=7.8,1.5Hz,1H),7.37-7.32(m,2H),7.25(m,1H),2 .78-2.71(m,1H),2.61(m,1H),2.51-2.43(m,1H),2.08-2.0(m,1H),1.88-1.63(m,4H).

[0055] Step 5: Compound D (1.11 g, 5 mmol) was dissolved in 2 ml of methanol, L-tartaric acid (2.5 mmol) was added, the mixture was stirred for 1 hour, and added dropwise to 10 ml of acetone, allowed to stand for crystallization, and filtered to obtain crystals of L-tartrate salt. The obtained L-tartrate salt crystals were recrystallized three more times, and then the crystals were added to sodium bicarbonate solution to neutralize them, and extracted with EA to obtain 165 mg of optically pure compound E(R)-demethylketamine, with an optical purity of 98.3% ee% by chiral HPLC and a yield of 15%.

[0056] Chiral HPLC detection step: Compound E and the control racemic compound D (1 mg each) were dissolved in 1 mL of ethanol and subjected to normal phase homogeneous analysis on an Agilent 1260-A high performance liquid chromatography column: Chiralcel-AD-H (4.6 mm x 250 mm), mobile phase A: (n-hexane + 0.1% diethylamine), mobile phase B: (ethanol + 0.1% diethylamine), A:B = 40:60, flow rate: 1 mL / min. For compound E, the retention time of the R isomer was 6.8 min, and the retention time of the corresponding S isomer was 5.3 min.

[0057] Step 6: Compound E (2.23 g, 10 mmol) was added to 60 mL of THF, triethylamine (2.7 mL, 20 mmol) and BocO (3.3 g, 15 mmol) were added, refluxed for 6 hours, cooled, spin-dried and passed through a silica gel column to give compound F (2.92 g), with a yield of 90%. 1 HNMR (400MHz, CDCl3): δ7.81(d,J=8.1Hz,1H),7.40-7.28(m,2H),7.24-7.12(m,1H),6.57(s,1H),3 .82(d,J=14.4Hz,1H),2.45-2.36(m,1H),2.28(m,1H),2.04(m,1H),1.89-1.56(m,4H),1.27(s,9H). 13 CNMR (100MHz, CDCl3): δ207.9,152.3,134.5,132.6,130.3,130.0,128.3,125.2,78.0,66.1,38.5,37.4,29.7,27.2,20.9.

[0058] Step 7: Compound F (2.91 g, 9 mmol) was added to 60 ml of dry THF, cooled to -78°C under argon protection, added with 5 ml of HMPA, then slowly added dropwise with 2 M LDA in THF (12 ml, 24 mmol), stirred for 30-40 minutes, then slowly warmed to -30°C, stirred for 1 hour, then cooled to -78°C, added with trimethylchlorosilane TMSCl (2.6 g, 24 mmol), slowly warmed to -50°C, stirred for 3 hours, added with saturated ammonium chloride solution, returned to room temperature, concentrated the THF solvent, added EA for extraction, added anhydrous Na2SO4 to the organic phase for drying, spun dry the solvent, dried in vacuum, and the resulting oil was diluted with 100 mL of anhydrous DCM. ml was added to dissolve, cooled to -15℃, under argon protection, mCPBA (2.5g, 11mmol) was added, stirred for 1 hour, then warmed to room temperature, DCM 50ml was added, stirred for another 1 hour, then saturated sodium thiosulfate and sodium bicarbonate solution (1:1) was added, extracted with DCM, the solvent was spin-dried and vacuum-dried, the obtained oil was further added with THF 100ml to dissolve, then cooled to -5℃, tetrabutylammonium fluoride (3g, 11.4mmol) was added, stirred for 30 minutes, NaHCO3 saturated solution was added, extracted with EA, the solvent was spin-dried and vacuum-dried, passed through a silica gel column to obtain compound G1.92G, with a yield of 65%. 1 HNMR (400MHz, CDCl3): δ7.81(d,J=7.8Hz,1H),7.34(m,2H),7.24(m,1H),6.60(s,1H),4.12(dd,J=11.7,6.8Hz,1H) ,3.87(d,J=14.4Hz,1H),3.38(m,1H),2.36(m,1H),1.74(m,2H),1.68-1.57(m,1H),1.55-1.40(m,1H),1.30(s,9H). 13 CNMR(100MHz, CDCl3):209.8,153.2,134.1,133.6,131.3,130.8,129.5,126.2,79.3,72.2,66.5,40.3,38.7,28.1,19.4.

[0059] Step 8: Compound G (680 mg) was dissolved in 5 mL of dry THF, and HCl gas was introduced at room temperature until saturation and stirred for 4 hours. 20 mL of dry diethyl ether was added, and after crystals were precipitated, the crystals were filtered to obtain 520 mg of compound H, the hydrochloride salt of (2R,6R)-6-hydroxydemethylketamine (HNK), with a yield of 95%. 1 HNMR (400MHz, CD3OD): δ7.85(m,1H), 7.65-7.51(m,3H), 4.28(m,1H), 3.19(m,1H), 2.30(m,1H), 1.81-1.72(m,2H), 1.64-1.51(m,2H).

[0060] Example 2: Synthesis of Compound I6 [ka] Compound G (170 mg, 0.5 mmol) was dissolved in 3 mL of dry THF, and dry triethylamine (0.28 mL, 2 mmol) was added, followed by addition of 3-furancarbonyl chloride (130 mg, 1 mmol) under ice bath conditions, followed by gradually warming to room temperature over 1 hour, stirring overnight, followed by addition of sodium bicarbonate solution, extraction with EA, spin-drying the solvent and vacuum-drying, and passing through a silica gel column to obtain compound H6, N-Boc-(2R,6R)-6-(3-furan)methanoyldemethylketamine, 173 mg, with a yield of 80%. 1 HNMR(400MHz,CDCl3):8.11(br,1H),7.81-7.79(brs,1H),7.42-7.28(m,4H),6.67(brs,1H),6.63( m,1H),5.35-5.31(m,1H),3.92-3.87(m,1H),2.39-2.33(m,1H),1.94-1.74(m,4H),1.30(brs,9H). 13 CNMR(100MHz,CDCl3):202.5,168.5,161.4,153.3,148.4,143.8,134.3,133.7,13 1.4,131.1,129.8,126.3,118.5,109.1,79.4,73.5,67.2,38.5,35.8,28.2,19.8.

[0061] Compound H6 (170 mg) was dissolved in 3 mL of dry THF, and HCl gas was introduced at room temperature until saturation. The mixture was stirred for 4 hours, and 15 to 20 mL of dry diethyl ether was added. After crystals were precipitated, the mixture was filtered under vacuum to obtain 124 mg of compound I6 (2R,6R)-6-(3-furan)methanoyldemethylketamine hydrochloride in a yield of 86%. 1 HNMR(400MHz,CD3OD):9.02(brs,3H),8.09(s,1H),7.79(s,1H),7.43-7.40(m,4H), 6.75(br,1H),5.39(m,1H),3.76-3.54(m,1H),2.41-2.32(m,2H),2.10-1.93(m,3H) 13 CNMR (100MHz, CD3OD): δ200.2,168.5,161.3,148.8,144.0,136.9,134.8,132.1,131.5,129.3,128.4,118.5,110.0,73.6,68.2,37.3,35.1,19.5.

[0062] Example 3: Synthesis of Compounds C and D [ka] Compounds C and D were prepared by the following preparative methods. [ka]

[0063] Example 4: Activity Test 1. Forced swimming test Mice were transferred to the experimental room 1 h before the forced swimming test (FST). The test was performed under normal light conditions and monitored by a digital camera. During the test, mice were placed in clear glass cylinders (28.5 cm high, 14 cm diameter) filled with 20 cm of water (23 ± 1 °C). On the first day, mice were trained for 6 min and then removed from the cylinder. On the second day, mice were administered saline, HNK, I6, C, and D and their immobility time was measured at different time intervals. During the last 4 min of the entire 6-min swimming test, immobility time, defined as passive floating without any other movement other than the movement required to keep the animal's head above water, was recorded by EthoVision XT of the Noldus system (Noldus, The Netherlands). After every 2-3 tests, the water in the bottles was replaced. After the swimming test, mice were removed from the water and dried under an infrared lamp.

[0064] Mice were intragastrically administered 1 mg (A), 10 mg (B) and 30 mg (C) of HNK or I6, respectively, and the immobility time was measured 1 hour and 7 days later. Percentage of immobility time is expressed as mean ± SEM. *p<0.05, **p<0.01 compared with baseline. N=8 for each group. Saline: saline group; I6, I6-treated group; HNK: 2R,6R-hydroxynorketamine-treated group.

[0065] 2. Addictive research material and method Animals: 8-12 week old C57BL / 6J male mice were randomly divided into groups, 10 mice per group, weighing 18-22g, kept at room temperature (22±1℃), humidity (50±10)%, light exposure time 8:00-20:00, drinking water was freely available to the mice, and they were allowed to acclimate to the experimental environment for at least 2-3 days before the experiment. All experiments were performed from 8:00 to 16:00.

[0066] Behavioral sensitization experiments: 1.1 Small animal spontaneous activity measurement: The animal spontaneous activity infrared analysis system consists of a spontaneous activity box, an infrared probe device, and a data collection system. The size of the spontaneous activity box is 40cm x 40cm x 65cm, and it is light- and sound-proof and has a ventilation means. The activity state of the animals was recorded by an infrared probe, and the number of spontaneous activities of the animals was calculated. To measure the effect of medicines on mouse spontaneous activity, the mice were randomly divided into 4 groups of 10 mice each. Groups: vehicle, I6, C, D (5.0, 10.0, 30.0mg / kg), mor (10mg / kg). Each group was administered once a day in the morning for 7 consecutive days, and then the administration was stopped for 7 days (no treatment). On the 15th day, the mice in each group were excited by gastric administration of Veh and medicine (5.0, 10.0, 30.0mg / kg). Immediately after administration on days 1, 7, and 15, spontaneous activity of the mice was measured within 1 hour.

[0067] 1.2 CPP experiment: The three-chamber CPP system includes two black and white boxes (25cm×25cm×30cm) separated by a middle box (10cm×25cm×30cm). During the experiment, mice can enter the middle box and shuttle freely between the black and white boxes. There is a shuttle door measuring 5cm×5cm between both the black and white boxes and the middle box. The experiment is divided into three stages, pre-test, training, and test, using a bias procedure, and the environmental conditions in the boxes, such as light, color, and odor, are guaranteed to be consistent throughout the experiment.

[0068] Preliminary test: On days 1-3, the partitions in the boxes were opened, and all mice were subcutaneously injected with saline, then placed in the middle box and allowed to move freely in the box for 15 min once a day for 3 consecutive days. The time spent by the mice in each box was recorded to determine the natural preference tendency of the mice, and the mice were trained using the non-natural preference box as the drug-contingent box.

[0069] Training period: On days 4-9, the shuttle door was closed and the mice were randomly divided into groups of 10 mice each, Veh, mor, I6, C, D (5.0, 10.0, 30.0 mg / kg), and mor (10 mg / kg). In the morning of a single day, all mice were intragastrically administered saline, and then immediately placed in the non-concomitant drug box (black box) for 45 minutes. In the afternoon of a single day, Veh, mor, I6, C, and D (5.0, 10.0, 30.0 mg / kg) were intragastrically administered, respectively, and then immediately placed in the concomitant drug box (white box) for 45 minutes. The training procedure on even days was reversed. The training interval between morning and afternoon training was more than 6 hours, and the training time was constant every day. Each group had 10 mice, and they were trained for 6 consecutive days.

[0070] Test period: On the 10th day, the partition was removed, and the mice were placed in the middle box and allowed to run freely. At the same time, the residence time of the mice in the white box was recorded for 15 minutes.

[0071] Statistical analysis: The experimental data are expressed as x ± SEM. Statistical analysis was performed using graphpad software. Comparisons between both groups were performed using t-tests, and comparisons between multiple groups were performed using one-way ANOVA analysis, followed by the LSD method.

[0072] 3. Place Preference Experiment Place preference was measured by a three-chamber system. Mice were trained with the non-natural preference box as the drug-accompanying box, and were administered saline (Veh), morphine (mor, 10 mg / kg), I6, C and D (5.0, 10.0, 30.0 mg / kg) during the training period. After six consecutive days of training, place preference was measured and the time spent in the white box within 15 minutes was recorded. Compared with the Veh group, *P<0.05 (n=10).

[0073] Example 5: Experimental Results 1. Mouse depressive-like behavior test results: HNK and I6 at 1 mg did not show antidepressant effects, HNK and I6 at 10 mg showed antidepressant effects, I6 showed sustained effects, and the efficacy was not substantially attenuated by day 7, however, the efficacy of HNK rapidly attenuated within 7 days and was substantially ineffective by day 7. HNK and I6 at 30 mg showed antidepressant effects, I6 showed sustained effects, and the efficacy was not substantially attenuated by day 7, whereas HNK rapidly attenuated within 7 days and was substantially ineffective by day 7.

[0074] Compounds C and D had no antidepressant effect at 30 mg.

[0075] Compared with the HNK-treated group, the I6-treated group had a significant antidepressant effect even after 7 days of administration, and the immobility time of the animals during forced swimming was reduced. The I6 group had a shorter immobility time. The 30 mg group showed a stronger tendency to decrease, but there was no significant difference between the 10 mg and 30 mg treatment groups. Compounds C and D did not have antidepressant effects.

[0076] 2. Addiction Test Different doses of I6 (5 mg, 10 mg, 30 mg) did not show any behavioral sensitizing effect in mice.

[0077] Different doses (5 mg, 10 mg, 30 mg) of C and D showed behavioral sensitization effects in mice.

[0078] 3. Place Preference Experiment Different doses of I6 (5 mg, 10 mg, 30 mg) did not induce place preference in mice.

[0079] Different doses (5 mg, 10 mg, 30 mg) of C and D induced place preference in mice.

[0080] The technical features of the above embodiments can be combined in any manner. For the sake of brevity, not all possible combinations of the technical features of the above embodiments are described. However, as long as no contradiction arises in the combination of these technical features, they should be considered to be within the scope of the present specification.

[0081] The above examples only show some embodiments of the present invention, and the description is more specific and detailed, but should not be understood as limiting the scope of the claims. However, those skilled in the art can make some modifications and improvements without departing from the gist of the present invention, which are within the scope of protection of the present invention. Therefore, the scope of protection of this patent application should be defined by the appended claims. The present invention provides, for example, the following items. (Item 1) A compound having a structure represented by Formula I, a salt, stereoisomer, or tautomer thereof. [ka] (In the formula, m is an integer from 0 to 3 and n is an integer from 0 to 4; R 1 and R 2 each independently represents H, a halogen atom, a hydroxyl group, an amino group, a cyano group, a substituted or unsubstituted C 1 -C 6 Alkyl groups, substituted or unsubstituted C 2 -C 6 Alkenyl groups, substituted or unsubstituted C 2 -C 6 Alkynyl groups, substituted or unsubstituted C 3 -C 10 Cycloalkyl groups, substituted or unsubstituted C 2 -C 10 Heterocyclic groups, substituted or unsubstituted C 1 -C 6 Alkoxy groups, substituted or unsubstituted mono- and di-C 1 -C 6 one or more selected from an alkylamino group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heteroaryl group; R 3 is a halogen; R 4 is H, substituted or unsubstituted C 1 -C 6 Alkyl groups, substituted or unsubstituted C 1 -C 8 acyl group, a substituted or unsubstituted aryl acyl group, or a substituted or unsubstituted heteroaryl acyl group; R 5 is a substituted or unsubstituted C 3 -C 10 Cycloalkyl groups, substituted or unsubstituted C 2 -C 10 selected from a heterocyclic group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heteroaryl group; R 6 is H, substituted or unsubstituted C 1 -C 6 Alkyl groups, substituted or unsubstituted C 2-C 6 Alkenyl groups, substituted or unsubstituted C 2 -C 6 Alkynyl groups, substituted or unsubstituted C 3 -C 10 Cycloalkyl groups, substituted or unsubstituted C 2 -C 10 Heterocyclic groups, substituted or unsubstituted aryl groups, substituted or unsubstituted heteroaryl groups, substituted or unsubstituted C 1 -C 8 acyl group, a substituted or unsubstituted aryl acyl group, or a substituted or unsubstituted heteroaryl acyl group; The substitutions are OH;NH 2 ;C 1 -C 10 Alkyl, alkenyl or alkynyl group; C 1 -C 10 Alkylamine group;Mercapto group;C 1 -C 10 Alkylmercapto group; C 1 -C 20 Alkoxy group; C 1 -C 10 Carbonyl group; C 3 -C 10 Cycloalkyl groups; 3-10 membered heterocyclic groups having one or more heteroatoms selected from N, S, O, and P; C 6 -C 20 Aryl group; C 2 -C 20 heteroaryl group; nitrocyano group, or halogen substituted). (Item 2) The compound according to item 1, characterized in that it has a structure represented by formula II.

change

change

change

change

change

change

change

change

change

change

Claims

1. A compound having a structure represented by Formula III, a salt, stereoisomer, or tautomer thereof. 【Chemistry 18】 (In the formula, m is an integer from 0 to 3, n is an integer from 0 to 4, and p is an integer from 0 to 3; R 1 and R 2 each independently represents H, a halogen atom, a hydroxyl group, an amino group, a cyano group, a substituted or unsubstituted C 1 -C 6 Alkyl group, substituted or unsubstituted C 2 -C 6 Alkenyl group, substituted or unsubstituted C 2 -C 6 Alkynyl group, substituted or unsubstituted C 3 -C 10 Cycloalkyl groups, substituted or unsubstituted C 2 -C 10 Heterocyclic group, substituted or unsubstituted C 1 -C 6 Alkoxy groups, substituted or unsubstituted mono- and di-C 1 -C 6 one or more selected from an alkylamino group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heteroaryl group; R 3 is a halogen; R 4 is H, substituted or unsubstituted C 1 -C 6 Alkyl group, substituted or unsubstituted C 1 -C 8 acyl group, a substituted or unsubstituted aryl acyl group, or a substituted or unsubstituted heteroaryl acyl group; R 6 is H, substituted or unsubstituted C 1 -C 6 Alkyl group, substituted or unsubstituted C 2 -C 6 Alkenyl group, substituted or unsubstituted C 2 -C 6 Alkynyl group, substituted or unsubstituted C 3 -C 10 Cycloalkyl groups, substituted or unsubstituted C 2 -C 10 Heterocyclic groups, substituted or unsubstituted aryl groups, substituted or unsubstituted heteroaryl groups, substituted or unsubstituted C 1 -C 8 acyl group, a substituted or unsubstituted aryl acyl group, or a substituted or unsubstituted heteroaryl acyl group; The substitutions are OH; NH 2 ; C 1 -C 10 an alkyl group, an alkenyl group, or an alkynyl group; 1 -C 10 Alkylamine group; mercapto group; C 1 -C 10 Alkylmercapto group; C 1 -C 20 Alkoxy group; C 1 -C 10 Carbonyl group; C 3 -C 10 Cycloalkyl groups; 3-10 membered heterocyclic groups having one or more heteroatoms selected from N, S, O, and P; C 6 -C 20 Aryl group; C 2 -C 20 Heteroaryl group; substituted with nitro, cyano, or halogen

2. A compound having a structure represented by Formula IV, a salt, stereoisomer, or tautomer thereof. 【Chemistry 19】 (In the formula, m is an integer from 0 to 3, n is an integer from 0 to 4, and p is an integer from 0 to 3; R 1 and R 2 each independently represents H, a halogen atom, a hydroxyl group, an amino group, a cyano group, a substituted or unsubstituted C 1 -C 6 Alkyl group, substituted or unsubstituted C 2 -C 6 Alkenyl group, substituted or unsubstituted C 2 -C 6 Alkynyl group, substituted or unsubstituted C 3 -C 10 Cycloalkyl groups, substituted or unsubstituted C 2 -C 10 Heterocyclic group, substituted or unsubstituted C 1 -C 6 Alkoxy groups, substituted or unsubstituted mono- and di-C 1 -C 6 one or more selected from an alkylamino group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heteroaryl group; R 3 is a halogen; R 4 is H, substituted or unsubstituted C 1 -C 6 Alkyl group, substituted or unsubstituted C 1 -C 8 acyl group, a substituted or unsubstituted aryl acyl group, or a substituted or unsubstituted heteroaryl acyl group; R 6 is H, substituted or unsubstituted C 1 -C 6 Alkyl group, substituted or unsubstituted C 2 -C 6 Alkenyl group, substituted or unsubstituted C 2 -C 6 Alkynyl group, substituted or unsubstituted C 3 -C 10 Cycloalkyl groups, substituted or unsubstituted C 2 -C 10 Heterocyclic groups, substituted or unsubstituted aryl groups, substituted or unsubstituted heteroaryl groups, substituted or unsubstituted C 1 -C 8 acyl group, a substituted or unsubstituted aryl acyl group, or a substituted or unsubstituted heteroaryl acyl group; The substitutions are OH; NH 2 ; C 1 -C 10 an alkyl group, an alkenyl group, or an alkynyl group; 1 -C 10 Alkylamine group; mercapto group; C 1 -C 10 Alkylmercapto group; C 1 -C 20 Alkoxy group; C 1 -C 10 Carbonyl group; C 3 -C 10 Cycloalkyl groups; 3-10 membered heterocyclic groups having one or more heteroatoms selected from N, S, O, and P; C 6 -C 20 Aryl group; C 2 -C 20 Heteroaryl group; substituted with nitro, cyano, or halogen

3. A compound such as that shown below. 【Chemistry 20】

4. A compound such as that shown below. 【Chemistry 21】

5. A compound having the structural formula: or a salt, stereoisomer, or tautomer thereof. 【Chemical 22】 (In the formula, R 7 is H or Boc)

6. 6. The compound of claim 5, characterized in that it has the structure: 【Chemistry 23】

7. 7. The compound according to claim 5 or 6, characterized in that it has the structure: 【Chemistry 24】 or 【Chemistry 25】

8. A pharmaceutical composition comprising a compound according to any one of claims 1-4, a salt, a stereoisomer, or a tautomer thereof, optionally further comprising a pharma- ceutically acceptable carrier.

9. A method for producing a compound, characterized in that: 【Chemistry 26】

10. A pharmaceutical for anesthesia, analgesia, improvement of cognitive function, lung protection, antidepressant, improvement of anxiety and post-traumatic stress syndrome, prevention or treatment of amyotrophic lateral sclerosis, and complex regional pain syndrome, comprising a compound according to any one of claims 1 to 4, or a pharmaceutical composition according to claim 8.

11. The pharmaceutical composition according to claim 10, wherein the pain includes chronic pain or neuropathic pain, the depression includes bipolar depression and major depression, and the improvement of cognitive function includes prevention or treatment of Alzheimer's disease and Parkinson's disease.

Citation Information

Patent Citations

  • The use of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (r,s)- ketamine in the treatment of depression and neuropathic pain

    CN104395283A

  • Use of (2R,6R)-hydroxynorketamine, (S)-dehydronorketamine and other (R,S)-ketamine stereoisomers (dehydro and hydroxylated metabolites) in the treatment of depression and neuropathic pain

    JP2015501302A

  • Crystalline forms and synthesis of (2R,6R)-hydroxynorketamine and (2S,6S)-hydroxynorketamine

    JP2019510768A